🚀 VC round data is live in beta, check it out!
Profarma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Profarma and similar public comparables like Fangzhou, Green Cross Health, MARX Biotech, BlueMTec and more.
Profarma Overview
About Profarma
Profarma Distribuidora De Produtos Farmaceuticos SA is a Brazil-based company. It is engaged in wholesale and distribution of pharmaceuticals, cosmetics and similar products, and toiletries. Profarma also holds interests in other companies, regardless of their business sector. The company through its logistics department distributes products in the South, Southeast, Northeast and Center-West regions of Brazil. The firm operates in the pharmaceutical distribution, hospital and specialty, retail segments.
Founded
1961
HQ
Employees
6.3K
Website
Sectors
Financials (FY)
EV
$428M
Profarma Financials
Profarma reported last fiscal year revenue of $2B and EBITDA of $104M.
In the same fiscal year, Profarma generated $350M in gross profit, $104M in EBITDA, and $24M in net income.
Profarma P&L
In the most recent fiscal year, Profarma reported revenue of $2B and EBITDA of $104M.
Profarma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $2B | XXX | XXX | XXX |
| Gross Profit | — | XXX | $350M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 15% | XXX | XXX | XXX |
| EBITDA | — | XXX | $104M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 5% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 3% | XXX | XXX | XXX |
| Net Profit | — | XXX | $24M | XXX | XXX | XXX |
| Net Margin | — | XXX | 1% | XXX | XXX | XXX |
| Net Debt | — | — | $128M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Profarma Stock Performance
Profarma has current market cap of $195M, and enterprise value of $428M.
Market Cap Evolution
Profarma's stock price is $1.59.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $428M | $195M | -0.6% | XXX | XXX | XXX | $0.19 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialProfarma Valuation Multiples
Profarma trades at 0.2x EV/Revenue multiple, and 4.1x EV/EBITDA.
Profarma Financial Valuation Multiples
As of April 21, 2026, Profarma has market cap of $195M and EV of $428M.
Equity research analysts estimate Profarma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Profarma has a P/E ratio of 8.2x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $195M | XXX | $195M | XXX | XXX | XXX |
| EV (current) | $428M | XXX | $428M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 0.2x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 4.1x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 6.1x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 1.2x | XXX | XXX | XXX |
| P/E | — | XXX | 8.2x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 5.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Profarma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Profarma Margins & Growth Rates
Profarma's revenue in the last fiscal year grew by 13%.
Profarma's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.0M for the same period.
Profarma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 13% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 5% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 29% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 12% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Profarma Public Comps
See public comps and valuation multiples for other Pharmacies comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Profarma | XXX | XXX | XXX | XXX | XXX | XXX |
| Fangzhou | XXX | XXX | XXX | XXX | XXX | XXX |
| Green Cross Health | XXX | XXX | XXX | XXX | XXX | XXX |
| MARX Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| BlueMTec | XXX | XXX | XXX | XXX | XXX | XXX |
| d1000 | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Profarma M&A Activity
Profarma acquired XXX companies to date.
Last acquisition by Profarma was on XXXXXXXX, XXXXX. Profarma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Profarma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialProfarma Investment Activity
Profarma invested in XXX companies to date.
Profarma made its latest investment on XXXXXXXX, XXXXX. Profarma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Profarma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Profarma
| When was Profarma founded? | Profarma was founded in 1961. |
| Where is Profarma headquartered? | Profarma is headquartered in Brazil. |
| How many employees does Profarma have? | As of today, Profarma has over 6K employees. |
| Is Profarma publicly listed? | Yes, Profarma is a public company listed on B3. |
| What is the stock symbol of Profarma? | Profarma trades under PFRM3 ticker. |
| When did Profarma go public? | Profarma went public in 2006. |
| Who are competitors of Profarma? | Profarma main competitors are Fangzhou, Green Cross Health, MARX Biotech, BlueMTec. |
| What is the current market cap of Profarma? | Profarma's current market cap is $195M. |
| What is the current revenue of Profarma? | Profarma's last fiscal year revenue is $2B. |
| What is the current EV/Revenue multiple of Profarma? | Current revenue multiple of Profarma is 0.2x. |
| Is Profarma profitable? | No, Profarma is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.